Comorbidities and Safety Events in Patients With Systemic Lupus Erythematosus (EULAR 2023) - Apr 2, 2023 - Abstract #POS1498; Pres time: Jun 3, 2023; 10:30 AM - 11:30 AM; Location: Poster View; "Use of second-line (methotrexate, azathioprine, leflunomide) and third-line (belimumab, anifrolumab, mycophenolate mofetil, mycophenolic acid, tacrolimus, cyclosporine, voclosporin, rituximab) SLE therapies were less common (29% and 30%, respectively). SLE-related systemic inflammation, comorbidities, and effects of SLE treatment (both positive and negative) likely contribute to patients' risk profiles. Disease activity cutoffs: No activity (SLEDAI=0), low (SLEDAI=1-5), moderate (SLEDAI=6-10), severe (SLEDAI=11+)"
Clinical • Acute Kidney Injury • Anemia • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Depression • Dyslipidemia • Endocrine Disorders • Epilepsy • Fibromyalgia • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Liver Failure • Lupus • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Obesity • Oncology • Pain • Psychiatry • Renal Disease • Rheumatoid Arthritis • Sjogren's Syndrome • Systemic Lupus Erythematosus
|
|
W. Krueger 1; D. Feger1; A. Friedman2; T. Doan2; K. D’silva2
|